Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Obesity 1Motor Activity 1Locally Advanced Head and Neck Squamous Cell Carcinoma 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Sunitinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Resistance Training × 30 days × Clear all
NCT07159815 2026-06-01

REACT

Inland Norway University of Applied Sciences

Phase NA Active not recruiting
160 enrolled
Tumor-Agnostic

Neoplasms

NCT07606313 2026-05-26

ACES

OHSU Knight Cancer Institute

Phase NA Not yet recruiting
150 enrolled

Motor Activity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡